The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88 for nivolumab/ipilimumab vs. nivolumab. 2. Pooled OR for grade 3-4 adverse events was found to be 1.84 for the combination compared to monotherapy Evidence Rating Level: 1 (Excellent) Study Rundown: Nivolumab/ipilimumab combination therapy has demonstrated improved progression-free survival (PFS) and
An overview of data presented at ESMO GI 2023 on combined botensilimab and balstilimab therapy in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.